A Multi-center Study of Folfox4 Combined With Recombinant Human Endostatin(Endostar)in Advanced Colorectal Cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- Time to progression
研究概览
简要总结
FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer
详细描述
Endostar is free supported by Shangdong Simcere Medgene biotech co.,Ltd. Endostar combination with Chemotherapy has been the first line treatment regimen to advanced NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. China NCCN colon or rectal cancer clinical practice guideline recommends Chemotherapy plus angiogenesis inhibitor as the first line treatment scheme. So we design FOLFOX4 plus Endostar to treat advanced colorectal cancer to research the RR and safety. We believe this treatment regimen may be a new approach to the advanced colorectal cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically or cytologically confirmed metastatic CRC
- •Measurable disease according to Response Criteria In Solid Tumours (RECIST)
- •Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status
- •Age 18~75
- •Life expectancy > 3 months
- •Signed informed consent (IC)
- •Adequate haematological and biological functions
排除标准
- •Pregnant or lactating women
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs
- •Neuropathy, brain, or leptomeningeal involvement
- •Treatment with any biologic, cytotoxic, radiation , or hormonal therapy within four weeks.
- •Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia
- •Uncontrolled significant comorbid conditions and previous radiotherapy
研究组 & 干预措施
Folfox4 plus Endostar
干预措施: Folfox4 plus recombinant human endostatin (Endostar) (Drug)
结局指标
主要结局
Time to progression
时间窗: every two cycles
次要结局
未报告次要终点